Onesource Specialty Pharma

1,686.70
+16.70
(1.00%)
Market Cap
19,301.90 Cr
EPS
-94.15
PE Ratio
236.44
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,800.00
52 Week Low
1,209.95
PB Ratio
3.29
Debt to Equity
1.22
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,683.60
#1 4,03,952.00
35.21
#1 49,887.20
12.06
#1 9,648
-18.99
40.74
6,483.00
1,72,103.30
78.53
8,184.00
0.89
1,600
23.05
63.44
1,484.20
1,19,866.20
22.74
26,520.70
14.17
4,155
30.28
47.86
3,174.70
1,07,446.30
55.70
10,785.70
11.59
1,656
10.91
43.82
1,230.10
1,02,646.40
#1 18.15
28,905.40
12.36
5,578
21.14
62.40
2,432.40
1,00,355.60
50.56
10,615.60
19.57
1,942
-10.91
44.37
908.60
91,426.40
19.56
19,831.50
13.82
3,831
-0.19
56.78
1,978.90
90,344.90
27.54
20,141.50
#1 19.94
1,936
#1 112.49
44.10
1,197.10
69,527.80
19.71
29,559.20
17.55
3,169
-10.04
50.83
30,795.00
65,437.20
46.30
6,097.20
10.80
1,201
27.83
54.40
Forecast
Actual
Growth Rate
Revenue Growth
325.36 %
Net Income Growth
-12.01 %
Cash Flow Change
34.18 %
ROE
74.62 %
ROCE
26.56 %
EBITDA Margin (Avg.)
-87.50 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
10
34
88
76
80
338
399
429
Expenses
80
105
173
76
73
263
351
244
EBITDA
-70
-71
-85
-0
7
76
48
185
Operating Profit %
-800 %
-210 %
-207 %
-4 %
7 %
21 %
11 %
43 %
Depreciation
19
18
20
20
19
68
69
69
Interest
18
25
26
21
20
45
46
33
Profit Before Tax
-107
-114
-130
-40
-33
-38
-67
83
Tax
0
0
0
0
0
5
2
-16
Net Profit
-107
-114
-130
-40
-33
-42
-69
99
EPS in ₹
0.00
-27.37
-31.32
-9.67
-7.90
-10.13
-6.31
8.61

Balance Sheet

Balance Sheet
2021
2022
2023
2024
Total Assets
1,258
2,442
2,009
1,309
Fixed Assets
633
1,231
1,361
863
Current Assets
99
511
228
176
Capital Work in Progress
431
490
335
188
Investments
0
0
5
20
Other Assets
195
722
309
238
Total Liabilities
1,258
2,442
2,009
1,309
Current Liabilities
161
809
865
631
Non Current Liabilities
321
621
358
282
Total Equity
776
1,013
786
396
Reserve & Surplus
775
1,009
781
392
Share Capital
2
3
4
4

Cash Flow

Cash Flow
2021
2022
2023
2024
Net Cash Flow
56
55
-112
13
Investing Activities
-207
-692
-68
511
Operating Activities
-118
-416
-163
-107
Financing Activities
381
1,162
118
-391

Share Holding

% Holding
Dec 2024
Mar 2025
Promoter
37.77 %
34.25 %
FIIs
17.44 %
18.54 %
DIIs
12.56 %
18.04 %
Government
0.00 %
0.00 %
Public / Retail
13.05 %
12.96 %
Others
19.18 %
16.20 %
No of Share Holders
98,425
82,712

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
05 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 May 2025 1,591.50 1,593.00
29 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Jan 2025 0.00 1,536.60
06 Dec 2024 MERGER - DEMERGER Merger - Demerger
2:1
06 Dec 2024 0.00 0.00
06 Dec 2024 MERGER - DEMERGER Merger - Demerger
1:1515
06 Dec 2024 0.00 0.00
14 Feb 2024 CHANGE OF NAME Change Of Name
NA
14 Feb 2024 0.00 0.00

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
Announcement Under Regulation 30.May 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
Intimation Of Investor Meet Held On May 06 2025May 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Board Meeting Intimation for Prior Intimation Of Board MeetingApr 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 26, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotApr 25, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressApr 23, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 23, 2025
Update On Scheme Of ArrangementApr 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2025
Announcement Under Regulation 30 SEBI(LODR) Regulations 2015_UpdatesApr 09, 2025
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Mar 29, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderMar 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Feb 21, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
Intimation Of Financial Results For The Quarter Ended September 302024 In Reply To The Exchange CommunicationFeb 06, 2025
Intimation Of Transcript Of Investors CallFeb 04, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 31, 2025
Intimation Of Newspaper Advertisement Of Financial ResultsJan 30, 2025
Intimation Of The Link Of The Audio Recording Of The Investor Call Held On 29Th January 2025.Jan 30, 2025
Integrated Filing (Financial)Jan 29, 2025
Statement Of Investor Complaints For The Quarter Ended December 31 2024Jan 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 29, 2025
Results-Financial Results For The Quarter Ended December 31. 2024Jan 29, 2025
Board Meeting Outcome for Approval Of The Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended December 31 2024Jan 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2025
Intimation Under Regulation 30(5) Of SEBI (LODR) Regulations 2015Jan 25, 2025
As Per The Exchange Communication Standalone & Consolidated Financial Results Of The Company For The Quarter Ended September 30 2024Jan 25, 2025
Shareholding Pattern Of The Company For The Quarter Ended Spetember 30 2024Jan 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended December 312024Jan 24, 2025
Listing of Equity Shares of Onesource Specialty Pharma LtdJan 24, 2025

Technical Indicators

RSI(14)
Neutral
60.12
ATR(14)
Less Volatile
72.44
STOCH(9,6)
Neutral
71.62
STOCH RSI(14)
Overbought
95.44
MACD(12,26)
Bullish
6.44
ADX(14)
Weak Trend
21.60
UO(9)
Bearish
53.73
ROC(12)
Uptrend And Accelerating
3.26
WillR(14)
Neutral
-32.07